Background: Cytotoxic therapy appears to have improved short-term survival for patients with small-cell lung cancer, but little is known about the results for unselected patients and trends in long-term survival.
Introduction
Small-cell lung cancer (SCLC) accounts for approximately 20% of all lung tumours among males and 25% among females in southeastern Netherlands [1] . SCLC has the poorest prognosis of all lung cancer cell types, particularly because of the rapid growth rate and early metastatic spread [2, 3] ; median survival for selected and unselected patients is about 12 months for limited disease and only about six months for extensive disease [4] [5] [6] . Since the end of the 1970s chemotherapy has become therapy-of-first-choice except for those rare patients with a localised peripheral lesion which should be resected. With the improvement of cytotoxic therapy over the last two decades, survival for patients with SCLC appears to have improved [7] [8] [9] , but only little is known about trends in long-term survival for unselected patients [7, 10] . We studied treatment policy for and both short-term and long-term survival of unselected patients with SCLC diagnosed in southeastern Netherlands since 1975, the period of development of cytotoxic therapy.
Patients and methods
Data were obtained from the Eindhoven Cancer Registry, which contains data on patients with newly diagnosed cancer in the Dutch province of North Brabant and the northern part of the adjacent province of Limburg. The area is characterized by good access to specialised care (medically, financially and geographically) in community hospitals, served by three regional pathology laboratories and one Department of Radiotherapy [11] . Between 1975 and 1994 the number of chest physicians, who mainly treated these patients, increased from 10 to 20 per one million inhabitants. The data were derived directly from clinical records of the community hospitals and the Department of Radiotherapy, upon notification by pathological laboratories and hospital administrations. Despite the lack of 'Death Certificate Only' (DCO) cases, the infrastructure of the Dutch health care system has made it possible to establish cancer registries with a completeness exceeding 95% [12] .
Between 1975 and 1994 10,149 lung cancer patients were diagnosed in southeastern Netherlands: 7273 non-small-cell lung cancer, 1796 small-cell lung cancer, 471 other lung tumours and 609 clinically diagnosed lung tumours.
All patients with SCLC diagnosed up to 1992 (n = 1585) were included in survival analysis: there was active follow-up until April 1994. Of these 1585 SCLC patients, 30 (2%) were still alive and 1555 (98%) were dead; none were untraceable. Patients who were diagnosed at autopsy or died within the first month of diagnosis were excluded from the survival analysis (n = 242, 15%). Tumour stage at diagnosis was based on physical examination. Tumours were classified according to the Veterans Administration Lung Cancer Study Group (VALG) [13] . Two categories were considered: limited disease (confined to one hemithorax including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular lymph nodes) and extensive disease (any disease at sites beyond the definition of limited disease). Data on tumour stage collected since 1990 were used for this analysis.
Treatment (only recorded when given within the first six months, except for radiotherapy) was divided into five categories: surgery, chemotherapy alone, radiotherapy alone, chemotherapy + radiotherapy, and 'other or none', including palliative care other than surgery, chemotherapy or radiotherapy.
We analysed the trends in treatment policy and survival for SCLC since 1975. Some of the patients died of causes other than the underlying cancer, particularly long-term survivors and older patients, thus the observed survival (irrespective of the cause of death) may not always reflect the disease-specific survival. Since causes of death are not included in this cancer registry, it is not possible to calculate disease-specific survival. In order to estimate the latter, the relative survival rate was calculated as the ratio of the observed to the expected actuarial rates. Expected survival rates were estimated from life tables for regional male and female populations with the same five-year age groups (supplied by Statistics Netherlands). The risk of death due to small-cell lung cancer and the f-values of equality of relative survival patterns on the basis of maximum likelihood ratio tests were calculated using a program of the Finnish Cancer Registry [14, 15] . For patients younger than 70 years of age diagnosed between 1975 and 1989 the conditional relative five-year survival rates were computed for patients who were still alive after one, three, five and eight years. The standard errors of survival rates were calculated according to Greenwood's formula [16] .
Results

Distribution of prognostic factors
The general characteristics of the patients, according to period of diagnosis, are listed in Table 1 1994. The mean age remained about 65 years (range 31-92 years). For patients diagnosed between 1990 and 1994 the proportion with limited disease was 41% for patients younger than 70 years of age and 36% for those over 70, whereas the proportions with extensive disease were 38% and 33%, respectively. The proportion with disease of unknown stage was higher for older patients (31%) than for younger patients (21%). Most patients (58%) received chemotherapy, with or without irradiation, a proportion which almost tripled from 30% to 82% of patients younger than 70 and from 15% to 56% of those over 70. The proportion of patients who underwent surgical resection or irradiation decreased markedly in both age groups (Table 1) . Treatment for each stage of disease and for both age groups (1990-1994) is shown in Table 2 . Elderly patients (5=70 years) were treated less aggressively, especially those with extensive or unknown disease stage. Furthermore, patients with limited stage small-cell lung cancer more often underwent surgery or received a combination of chemotherapy and radiotherapy.
Survival
Of all patients with SCLC diagnosed between 1975 and 1992, 242 (15%) were diagnosed at autopsy or died within one month of diagnosis, i.e., 12% of patients younger than 70 and 22% of those over 70. For those alive after one month the median survival increased from five months in 1975-1979 to nine months in 1985-1989 and 1990-1992 . The improvement only applied for short-term ( < 2 years) survival (Figure 1 ). The overall two-year relative survival rate remained only 8%. The increase in short-term survival was found for both males and females and was most marked for patients younger than 70 years (Table 3) . Testing of equality of the two-year survival patterns showed a levelling off of the improvement for patients age <70 years 100 <? Ninety patients (6%) survived for at least two years. The distribution of prognostic factors at diagnosis for these 'long'-term survivors differed from that found for the initial group: the mean age was 3.5 years younger, there were more females (16% vs. 12%) and the proportion with a surgically resected tumour was also much higher (25% vs. 5%). Two of the 90 'long'-term survivors developed a second malignancy. One had a pancreatic tumour 4.2 years after diagnosis of the first tumour; the patient survived only two days after diagnosis of this second tumour. The other had a squamous cell lung tumour 6.2 years after diagnosis, with a survival of 4.6 years.
The relative five-year survival rate, calculated for patients younger than 70 years of age at diagnosis who were still alive after one, three, five, and eight years, respectively, increased from 12% conditional on being alive after one year to 61% conditional on being alive after eight years (Table 4 ). In southeastern Netherlands chemotherapy has been first-choice therapy for patients with SCLC since the beginning of the 1980s. Short-term survival (<2 years) has almost doubled since 1975, especially for patients younger than 70 years; however, 'long'-term survival (>2 years) remained poor and excess mortality for patients who were alive after eight years was 39%.
The improved short-term survival is likely to be due to the increased use of chemotherapy since the end of the 1970s. Cyclophosphamide-doxorubicin-etoposide (CDE) has been the standard combination in southeastern Netherlands and had not evolved to a platinum containing regimen during the study period. Nonetheless, despite initial chemosensitivity, the majority of patients relapse or develop a second tumour and die [17, 18] ; results of chemotherapy seem to have reached a plateau and ascending from here seems impossible with the current available tools [9] . The percentage patients receiving radiotherapy alone or radiotherapy after chemotherapy decreased, even though meta-analyses showed that survival for patients with limited disease who received chemotherapy and radiotherapy was significantly better than for those receiving chemotherapy alone [19, 20] .
Our data do not show an improvement in median survival over time for older patients, which may be due to less aggressive treatment because of poor performance status. The latter is related to the high prevalence of co-morbidity in these cases: according to unpublished data from our Cancer Registry, 60% of patients over 70 with small-cell lung cancer diagnosed between 1993 and 1995 in southeastern Netherlands had one or more serious co-morbid conditions such as cardiovascular diseases or chronic obstructive lung disease (COPD). The proportion receiving chemotherapy (of patients over 70) decreased slightly from 73% for those without concomitant diseases to 65% for those with two or more concomitant diseases. Nonetheless, in several other studies on unselected patients it was found that even elderly patients with co-morbidity are likely to benefit from combination chemotherapy [6, 21] . Moreover, doxorubicin appeared to have no influence on cardiac arrhythmias in small-cell lung cancer patients with cardiac disease [22] . In a Canadian study elderly patients were treated less aggressively than younger patients, but survival was similar for the two age groups [23] .
In our study only six percent of all SCLC patients (n = 90) survived for at least two years, a finding similar to that of the SEER (Surveillance, Epidemiology and End Results) project in the United States [24] . Two of these 'long'-term survivors developed a second malignancy, a non-small-cell lung tumour and a pancreatic tumour. In other studies non-small-cell lung cancer developed in 0.5% to 24% and other malignancies in 3% to 11% [9, 10, [25] [26] [27] [28] [29] [30] [31] . However, the numbers with second malignancies in these studies were very small. Conclusion: in southeastern Netherlands short-term survival of patients with small-cell lung cancer improved markedly up to the end of the 1980s, but a major impact on cure rates has not been achieved.
